Format

Send to

Choose Destination
Clin Epigenetics. 2017 Apr 26;9:44. doi: 10.1186/s13148-017-0343-5. eCollection 2017.

Circulating unmethylated insulin DNA as a potential non-invasive biomarker of beta cell death in type 1 Diabetes: a review and future prospect.

Author information

1
National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, No.1 Dahua Road, Dong Dan, Beijing, 100730 People's Republic of China.

Abstract

BACKGROUND:

The early detection of type 1 diabetes (T1D) largely depends on a reliable approach to monitor β cell loss. An effective way to evaluate the decline of β cell mass would allow early preventative intervention to preserve insulin secretion.

MAIN BODY:

Recent progress in the development of novel biomarkers, based on tissue-specific methylation patterns, has inspired relevant studies in T1D. In this review, we focus on the application of circulating β cell-derived unmethylated insulin (INS) DNA. Circulating β cell-derived unmethylated INS DNA has a potential clinical value for the early detection of T1D, surveillance of islet transplantation rejection, and evaluation of response to therapy. Utilizing differentiated methylation patterns in different organs and employing a wide variety of molecular technologies also provide insights into the interrogation of biomarkers in other diseases with massive tissue-specific cell loss.

CONCLUSION:

Circulating unmethylated INS DNA is a promising molecular biomarker for the early detection of T1D.

KEYWORDS:

Cell-free DNA; Early detection; Molecular biomarkers; Type 1 diabetes; Unmethylated insulin DNA

PMID:
28450972
PMCID:
PMC5405546
DOI:
10.1186/s13148-017-0343-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center